Intervention: Doconexent
Trial phase: Phase 1
SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 20
Group description: The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.

Docosahexaenoic acid (DHA): Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Male or females age 14-18 inclusive

Diagnosed with concussion due to sports-related injury. Concussion is defined as:

Direct blow to the head, face, neck or a blow elsewhere on the body with an "impulsive" force transmitted to the head.
Rapid onset of short-lived impairment of neurologic function in one or more of the following clinical domains that resolves spontaneously:

i. Symptoms: somatic (eg, headache), cognitive (eg, feeling like in a fog and/or emotional symptoms (eg, lability).

ii. Physical signs (eg, loss of consciousness, amnesia).

iii. Behavioral changes (eg, irritability).

iv. Cognitive impairment (eg, slowed reaction times).

v. Sleep disturbance (eg, drowsiness). c) No abnormality on standard structural neuroimaging studies, if such neuroimaging studies are completed for a clinically-indicated reason. Note: neuroimaging is not a part of this study protocol. Study participants will not undergo neuroimaging as part of this study.

Concussion within 4 days of enrollment
Presenting for treatment to the Sports Medicine Center at Children's Medical Center

Exclusion Criteria:

Subjects not actively participating in an organized sport at time of enrollment
Subjects who received a concussion from an event other than playing a sport (motor vehicle accident, fall, etc.)
Subjects who participate in or received a concussion during participation in motorized sports (i.e., motorcross, dirt biking, jet skiing, etc.)
Subjects with radiographic evidence of traumatic brain injury (i.e., skull fracture, intracranial hemorrhage, cerebral contusion, etc).
Subjects with a prior diagnosed concussion in the previous 6 months.
Pregnant women.
Subjects sensitive to aspirin
Subjects diagnosed with high blood pressure and currently being treated with blood pressure medications
Subjects allergic to soy bean oil or corn oil.
Subjects currently taking fish oil or DHA supplements.